Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 5, 2009, Pages

  Gelpi, Ricardo J ^a,b   Gao, Shumin ^a   Zhai, Peiyong ^a   Yan, Lin ^a   Hong, Chull ^a   Danridge, Lauren M A ^a   Ge, Hui ^a   Maejima, Yasahiro ^a   Donato, Martin ^b   Yokota, Mitsuhiro ^c   Molkentin, Jeffery D ^d   Vatner, Dorothy E ^a   Vatner, Stephen F ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Diastole; Hemodynamics; Hypertrophy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCINEURIN; CALCINEURIN INHIBITOR; CALCIUM; PHOSPHOLAMBAN; RYANODINE RECEPTOR; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC DISEASE; CHRONIC PRESSURE OVERLOAD; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE OVERLOAD; HEREDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SYSTOLIC BLOOD PRESSURE;

ANIMALS; AORTA; CALCINEURIN; CALCIUM-BINDING PROTEINS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIASTOLE; DISEASE MODELS, ANIMAL; ELASTICITY; HYPERTROPHY, LEFT VENTRICULAR; LIGATION; MICE; MICE, TRANSGENIC; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; PROTEINS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 70350433686     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00449.2009     Document Type: Article

References (34)

1. Brutsaert DL. Diastolic heart failure: perception of the syndrome and scope of the problem. Prog Cardiovasc Dis 49: 153-156, 2006.
2. 2+ handling in a calcineurin transgenic model of heart failure. Cardiovasc Res 54: 105-116, 2002.
3. Chu G, Kranias EG. Functional interplay between dual site phospholambam phosphorylation: insights from genetically altered mouse models. Basic Res Cardiol 97, Suppl 1: I43-I48, 2002. (Pubitemid 34624758)
4. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98: 3322-3327, 2001. (Pubitemid 32220844)
5. 2+-ATPases for cell viability and calcineurin-dependent regulation of calcium tolerance. Mol Microbiol 31: 545-556, 1999.
6. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61: 87-93, 2004. (Pubitemid 38056684)
7. Friedrich SP, Lorell BH, Rousseau MF, Hayashida W, Hess OM, Douglas PS, Gordon S, Keighley CS, Benedict C, Krayenbuehl HP. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 90: 2761-2771, 1994.
8. Grote-Wessels S, Baba HA, Boknik P, El-Armouche A, Fabritz L, Gillmann HJ, Kucerova D, Matus M, Muller FU, Neumann J, Schmitz M, Stumpel F, Theilmeier G, Wohlschlaeger J, Schmitz W, Kirchhefer U. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 79: 464-471, 2008.
9. Gupta RC, Mishra S, Yang XP, Sabbah HN. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem 269: 49-57, 2005. (Pubitemid 40287801)
10. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, Weiss RM, Kutschke W, Bassel-Duby R, Williams RS. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 277: 10251-10255, 2002. (Pubitemid 34968140)
11. Hirotani S, Zhai P, Tomita H, Galeotti J, Marquez JP, Gao S, Hong C, Yatani A, Avila J, Sadoshima J. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res 101: 1164-1174, 2007. (Pubitemid 350146443)
12. Hittinger L, Mirsky I, Shen YT, Patrick TA, Bishop SP, Vatner SF. Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. Circulation 92: 978-986, 1995.
13. Hittinger L, Shannon RP, Bishop SP, Gelpi RJ, Vatner SF. Subendomyocardial exhaustion of blood flow reserve and increased fibrosis in conscious dogs with heart failure. Circ Res 65: 971-980, 1989. (Pubitemid 19242649)
14. Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA, Molkentin JD. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 32: 697-709, 2000. (Pubitemid 30658937)
15. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999. (Pubitemid 29157342)
16. Mendoza I, Quintero FJ, Bressan RA, Hasegawa PM, Pardo JM. Activated calcineurin confers high tolerance to ion stress and alters the budding pattern and cell morphology of yeast cells. J Biol Chem 271: 23061-23067, 1996. (Pubitemid 26314739)
17. Mizuno Y, Kanou Y, Rogatcheva M, Imai T, Refetoff S, Seo H, Murata Y. Genomic organization of mouse ZAKI-4 gene that encodes ZAKI-4 alpha and beta isoforms, endogenous calcineurin inhibitors, and changes in the expression of these isoforms by thyroid hormone in adult mouse brain and heart. Eur J Endocrinol 150: 371-380, 2004. (Pubitemid 38443789)
18. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998. (Pubitemid 28180855)
19. Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 369: 486-488, 1994. (Pubitemid 2088233)
20. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98: 3328-3333, 2001. (Pubitemid 32220845)
21. Rothermel BA, Vega RB, Williams RS. The role of modulatory calcineurin- interacting proteins in calcineurin signaling. Trends Cardiovasc Med 13: 15-21, 2003.
22. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110: 271-279, 2002. (Pubitemid 34787364)
23. Semeniuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD, Duff HJ. Time-dependent systolic and diastolic function in mice overexpressing calcineurin. Am J Physiol Heart Circ Physiol 284: H425-H430, 2003.
24. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R, Komuro I. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100: 2449-2454, 1999. (Pubitemid 37411007)
25. Sulakhe PV, Vo XT, Morris TE, Pato MD, Khandelwal RL. Protein phosphorylation in rat cardiac microsomes: effects of inhibitors of protein kinase A and of phosphatases. Mol Cell Biochem 175: 109-115, 1997. (Pubitemid 27453342)
26. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690-1693, 1998. (Pubitemid 28435588)
27. Vatner SF, Shannon R, Hittinger L. Reduced subendocardial coronary reserve. A potential mechanism for impaired diastolic function in the hypertrophied and failing heart. Circulation 81: III8 -III14, 1990. (Pubitemid 20069389)
28. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. J Biol Chem 278: 36981-36984, 2003. (Pubitemid 37175209)
29. Watanuki S, Matsuda N, Sakuraya F, Jesmin S, Hattori Y. Protein kinase C modulation of the regulation of sarcoplasmic reticular function by protein kinase A-mediated phospholamban phosphorylation in diabetic rats. Br J Pharmacol 141: 347-359, 2004. (Pubitemid 38250905)
30. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110-118, 2004. (Pubitemid 38064105)
31. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82, 2002. (Pubitemid 34615941)
32. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112: 1395-1406, 2003. (Pubitemid 38057693)
33. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res 99: 528-536, 2006. (Pubitemid 44337825)
34. Zhai P, Gao S, Holle E, Yu X, Yatani A, Wagner T, Sadoshima J. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem 282: 33181-33191, 2007. (Pubitemid 350159328)